Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2

Journal of Pharmacology and Experimental Therapeutics

Volumn 296, Issue 2, 2001, Pages 558-566

  Riendeau, D ^a   Percival, M D ^a   Brideau, C ^a   Charleson, S ^a   Dube D ^a   Ethier, D ^a   Falgueyret, J P ^a   Friesen, R W ^a   Gordon, R ^a   Greig, G ^a   Guay, J ^a   Mancini, J ^a   Ouellet, M ^a   Wong, E ^a   Xu, L ^a   Boyce, S ^b   Visco, D ^b   Girard, Y ^a   Prasit, P ^a   Zamboni, R ^a   Rodger, I W ^a   Gresser, M ^a   Ford Hutchinson, A W ^a   Young, R N ^a   Chan, C C ^a   more..

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; INDOMETACIN; MELOXICAM; NAPROXEN; NIMESULIDE; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE B2; UNCLASSIFIED DRUG; VALDECOXIB;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; IC 50; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; SQUIRREL MONKEY; STOMACH DISEASE; THROMBOCYTE;

ALGORITHMS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; CHO CELLS; CRICETINAE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; IONOPHORES; ISOENZYMES; MALE; MEMBRANE PROTEINS; MICROSOMES, LIVER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; SULFONES; THROMBOXANE B2;

EID: 0035145462     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine
2. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
3. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
4. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
5. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
6. A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates
7. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase
8. Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays
9. Selective cyclooxygenase-2 inhibition by nimesulide in man
10. MK-0663 a highly selective inhibitor of COX-2 in humans
11. Antiinflammatory drug-induced small intestinal permeability: The rat is a suitable model
12. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
13. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
14. Meloxicam: Influence on arachidonic acid metabolism. Part 1. In vitro findings
15. Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats
16. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors
17. The cyclooxygenase isoforms: Structural insights into the conversion of arachidonic acid to prostaglandins
18. Kinetic basis for selective inhibition of cyclo-oxygenases
19. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors
20. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1
21. COX-2 inhibitors
22. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs
23. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells
24. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents
25. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
26. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
27. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
28. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms
29. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs
30. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings
31. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects
32. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
33. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib)
34. Purification and characterization of recombinant human cyclooxygenase-2
35. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor
36. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays
37. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
38. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs
39. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
40. 4-[5-Methyl-3-phenylisoxazol4-yl]-benzenesulfonamide, Valdecoxib: A potent and selective inhibitor of COX-2
41. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state
42. COX-2 inhibitors
43. Profile of JTE-522 as a human cyclooxygenase-2 inhibitor
44. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
45. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 → Arg and Ile523 → val mutation